The Ontario Ministry of Health has recently updated the Ontario Guidelines for Drug Submission and Evaluation (Guidelines). In an effort to reduce complexity and simplify their policy document, specific guidelines aiming to address individual product types are now available on the Ontario Ministry of Health website.... Read More

On July 11, 2017, the Executive Officer announced that as part of the 2017 Budget and the government’s ongoing commitment to provide better and faster access to high-quality health services, Ontario is proposing to create the OHIP+: Children and Youth Pharmacare Program. Under this program, the province would, as of January ... Read More

Effective November 1, 2016, the ministry is introducing the application of generic substitution to the Exceptional Access Program (EAP). Under this new policy, if an EAP drug has an interchangeable generic product designated through the Off-Formulary Interchangeable (OFI) mechanism, the ministry will only approve the funding of the generic product. Where ... Read More

The Ontario Public Drug Programs (OPDP) is publishing an addendum (Addendum #1) to the Ontario Guidelines for Drug Submission and Evaluation (Guidelines) to assist the manufacturers in making drug submissions to the OPDP. Addendum #1 contains information about the regulatory amendments that were recently approved by the Ontario government and ... Read More

Recent amendments have been made to the Ontario Regulation 201/96 under the Ontario Drug Benefit Act (‘ODBA Regulation’) and to Regulation 935 under the Drug Interchangeability and Dispensing Fee Act (‘DIDFA Regulation’). The amendments have been approved by the Ontario Government and come into force on October 1, 2016. A notice ... Read More

To help drug manufacturers prepare drug submissions, the Ministry of Health and Long-Term Care has updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines). The Guidelines take effect on October 6, 2016. All submissions received on or after this date must comply. The updated Guidelines reflect current regulatory and policy requirements ... Read More

The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, effective February 25, 2016, for the following indications: Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Plaque Psoriasis The LU criteria are posted in the eFormulary which can found on the ministry’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx The funding of ... Read More